Thomas E. Boyd

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

Ranjana H. Advani, Joseph J. Buggy, Jeff P. Sharman et al. · Journal of Clinical Oncology · 2012 · 1.1K citations · Full text

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial

Peter Hillmen, Tadeusz Robak, Ann Janssens et al. · The Lancet · 2015 · 337 citations

Hematological Malignancy, Immunohematology, Complement 1 +13

Randomized Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Sodium (Bcl-2 antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Susan O’Brien, Joseph O. Moore, Thomas E. Boyd et al. · Journal of Clinical Oncology · 2007 · 298 citations

Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer

Heather H. Cheng, Colin C. Pritchard, Thomas E. Boyd et al. · European Urology · 2015 · 260 citations · Full text

Biallelic Inactivation, Urology, Oncology +8

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold et al. · The Lancet Haematology · 2019 · 249 citations · Full text

Hematological Malignancy, Oncology, Hematology +6